Risk-Benefit Assessment of Methotrexate in the Treatment of Severe Psoriasis

Author： Kuijpers A.L.   van der Kerkhof P.C.M.  

Publisher： Adis International

ISSN： 1175-0561

Source： American Journal of Clinical Dermatology, Vol.1, Iss.1, 2000-01, pp. : 27-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis: A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials

By Leonardi Craig  

American Journal of Clinical Dermatology, Vol. 12, Iss. 5, 2011-10 ,pp. : 321-337

Adis International

Access to resources Recommend Favorite

Qualitative and Quantitative Assessment of the Benefit-Risk Ratio of Medium Potency Topical Corticosteroids In Vitro and In Vivo : Characterisation of Drugs with an Increased Benefit-Risk Ratio

By Schackert C.  

BioDrugs, Vol. 13, Iss. 4, 2000-04 ,pp. : 267-277

Adis International

Access to resources Recommend Favorite

Briakinumab for the Treatment of Plaque Psoriasis

By Traczewski Pawel   Rudnicka Lidia  

BioDrugs, Vol. 26, Iss. 1, 2012-02 ,pp. : 9-20

Adis International

Access to resources Recommend Favorite

Optimal Management of Severe Plaque Form of Psoriasis

By Fairhurst David A.  

American Journal of Clinical Dermatology, Vol. 6, Iss. 5, 2005-01 ,pp. : 283-294

Adis International

Access to resources Recommend Favorite

Spotlight on Ustekinumab in Moderate To Severe Plaque Psoriasis†

By Croxtall Jamie D.  

American Journal of Clinical Dermatology, Vol. 13, Iss. 2, 2012-04 ,pp. : 135-137

Adis International

Access to resources Recommend Favorite